scispace - formally typeset
J

Jing Pang

Researcher at University of Western Australia

Publications -  121
Citations -  2463

Jing Pang is an academic researcher from University of Western Australia. The author has contributed to research in topics: Medicine & Familial hypercholesterolemia. The author has an hindex of 27, co-authored 95 publications receiving 1738 citations. Previous affiliations of Jing Pang include Royal Perth Hospital & National Health and Medical Research Council.

Papers
More filters
Journal ArticleDOI

Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action

Katherine Wilemon, +94 more
- 02 Jan 2020 - 
TL;DR: The Global Call to Action on Familial Hypercholesterolemia thus represents individuals with FH, advocacy leaders, scientific experts, policy makers, and the original authors of the 1998 World Health Organization report.
Journal ArticleDOI

Cascade screening based on genetic testing is cost-effective: Evidence for the implementation of models of care for familial hypercholesterolemia

TL;DR: Analysis within an Australian context, demonstrates that cascade screening for FH, using genetic testing supplemented with the measurement of plasma low-density lipoprotein cholesterol concentrations and treatment with statins, is a cost-effective means of preventing CHD in families at risk of FH.
Journal ArticleDOI

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Antonio J. Vallejo-Vaz, +723 more
- 07 Sep 2021 - 
TL;DR: The European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (FHSC) global registry provides a platform for the global surveillance of familial hypercholesterololaemia through harmonisation and pooling of multinational data as discussed by the authors.
Journal ArticleDOI

Postprandial Hypertriglyceridemia and Cardiovascular Disease: Current and Future Therapies

TL;DR: New agents, such as dual peroxisome-proliferator-activated receptor α/δ agonists, diacylglycerol, inhibitors of diACYlglycersol acyltransferase 1 and microsomal triglyceride transfer protein, antisense oligonucleotides for apolipoprotein B-100 and apoliprotein C-III, and incretin-based therapies, may enhance the treatment of postprandial lipemia, but